|1.||Hypercalcemia (Milk Alkali Syndrome)
|2.||Chronic Kidney Failure (Chronic Renal Failure)
|1.||Chen, Herbert: 22 articles (01/2016 - 05/2002)|
|2.||Fukagawa, Masafumi: 18 articles (12/2015 - 09/2003)|
|3.||Tominaga, Yoshihiro: 14 articles (11/2013 - 03/2002)|
|4.||Sippel, Rebecca S: 12 articles (11/2015 - 05/2003)|
|5.||Hendy, Geoffrey N: 10 articles (07/2014 - 03/2002)|
|6.||Cole, David E C: 9 articles (07/2014 - 03/2002)|
|7.||Solorzano, Carmen C: 9 articles (03/2011 - 05/2004)|
|8.||Duh, Quan-Yang: 8 articles (01/2014 - 12/2002)|
|9.||Clark, Orlo H: 8 articles (01/2014 - 08/2002)|
|10.||Drüeke, Tilman B: 8 articles (12/2013 - 01/2002)|
01/01/1989 - "This simple and well-tolerated regimen almost completely eliminated oral aluminium exposure, effectively controlled plasma phosphate and calcium concentrations, and reduced hyperparathyroidism."
01/01/1983 - "The combined evaluation of serum iPTH and calcium may improve the diagnosis for hyperparathyroidism and was in our series helpful in making a correct diagnosis in 2 out of 7 patients who had histologically verified disease. "
01/01/1981 - "Although pathologic parathyroid tissue could not be identified it is concluded from postoperative normalisation of calcium levels that hyperparathyroidism had been cured by surgery. "
06/01/1974 - "Improved diagnosis of hyperparathyroidism: use of serum-ionized calcium and tubular reabsorption of calcium."
12/01/2001 - "a) To study the nature and severity of neuropsychiatric manifestations in patients of hyperparathyroidism before surgery and their outcome after surgery b) To study their correlation with levels of serum calcium. "
|2.||Parathyroid Hormone (Parathormone)IBA
01/01/2002 - "During the last five years, minimally invasive procedures have been adopted for the surgical treatment of hyperparathyroidism, because preoperative localization studies such as high-resolution ultrasonography and sestamibi scintigraphy, guidance by intraoperative scans, and the use of quick, intraoperative parathyroid hormone assay have improved. "
09/01/2011 - "Intraoperative parathyroid hormone (IoPTH) testing is useful in the management of hyperparathyroidism. "
08/01/1995 - "Comparing the drop in intact parathormone levels between cured patients and those with persistent hyperparathyroidism after surgery showed statistically significant differences. "
08/01/1984 - "These results demonstrate usefulness of homologous radioimmunoassay for human PTH(1-34) in diagnosis and management of hyperparathyroidism, as well as in studying the clearance of amino-terminal portion of PTH which is known to represent biological activity."
01/01/1983 - "Parathormone assay remains the "gold standard" for definitive diagnosis of hyperparathyroidism."
|3.||cinacalcet (Sensipar)FDA Link
02/01/2004 - "The present findings provide compelling evidence that cinacalcet HCl is a potent and stereoselective activator of the parathyroid CaR and, as such, might be beneficial in the treatment of hyperparathyroidism."
03/01/2015 - "At the end of the period of treatment with cinacalcet, for both variants of hyperparathyroidism, a statistically significant reduction in the overall number and in the diameter of renal stones was found. "
12/01/2010 - "Cinacalcet was effective in treating posttransplant hyperparathyroidism, resulting in decreased calcemia and transient decreased iPTH. "
03/01/2005 - "Cinacalcet HCl: a novel therapeutic for hyperparathyroidism."
11/27/2012 - "From nonrandomized studies, cinacalcet appears to be safe and effective for the treatment of posttransplant hyperparathyroidism. "
|4.||Vitamin DFDA LinkGeneric
12/01/1994 - "The i.v. bolus administration of 1 alpha hydroxylated vitamin D derivatives is effective in the treatment of uremic hyperparathyroidism. "
08/01/2011 - "Previous reports have indicated that Vitamin D status can be improved without adverse effects in hyperparathyroidism. "
07/01/2009 - "Treatment with vitamin D produced a slight improvement in the prevalence of hyperparathyroidism."
10/01/1987 - "A regression of hyperparathyroidism and improvement in vitamin D status are the cause of this phenomenon."
05/01/2014 - "Further study is needed to determine whether low vitamin D levels may be an etiologic factor associated with the development of hyperparathyroidism. "
|5.||Calcitriol (Calcijex)FDA LinkGeneric
03/12/1994 - "The administration of intravenous calcitriol at high and intermittent doses is effective in a considerable number of patients with hyperparathyroidism resistant to the classical oral schedules. "
01/01/1997 - "These data indicate that intermittent intensive calcitriol therapy, regardless of the route of administration, is effective in suppressing parathyroid activity in HD patients with mild or moderate hyperparathyroidism. "
01/01/1996 - "Calcitriol is effective in suppressing PTH levels in haemodialysis patients with hyperparathyroidism but has a low therapeutic index. "
11/01/1995 - "The current study evaluates the use of intravenous (IV) calcitriol in 10 patients with severe hyperparathyroidism (HPTH). "
06/01/2015 - "On the other hand, high serum TRAP5b concentrations did not seem to be affected by neither calcitriol treatment nor the severity of hyperparathyroidism. "
01/01/2015 - "The management of hyperparathyroidism in dialysis requires control of phosphorus level. "
01/01/2014 - "This case illustrates the risk of tertiary hyperparathyroidism as a complication of treatment for hypophosphataemia; it highlights the morbidity associated with hungry bone syndrome and provides novel insight into renal handling of phosphorus."
07/01/2009 - "This effect was mediated via a better control of hyperparathyroidism including serum Ca and phosphorus. "
05/01/1993 - "The importance of high plasma phosphorus levels in the pathogenesis of hyperparathyroidism is concisely discussed. "
01/01/1993 - "In three groups hyperparathyroidism was stimulated by the use of a high phosphorus (1.2%) diet (HPD). "
|7.||paricalcitol (Zemplar)FDA Link
09/01/2014 - "Suppression of PTH may be a useful strategy for skeletal improvement in XLH patients with hyperparathyroidism, and paricalcitol appears to be an effective adjunct to standard therapy in this setting. "
06/01/2013 - "Oral paricalcitol reduces the prevalence of posttransplant hyperparathyroidism: results of an open label randomized trial."
06/01/2013 - "One-year posttransplant, 29% of paricalcitol-treated subjects had hyperparathyroidism compared with 63% of untreated patients (p = 0.0005). "
01/01/2003 - "Severe hyperparathyroidism despite paricalcitol therapy: one-year follow-up."
06/01/2013 - "Oral paricalcitol is effective in decreasing posttransplant hyperparathyroidism and may have beneficial effects on renal allograft histology."
05/01/2005 - "Among the treatment groups, alfacalcidol significantly improved the hyperparathyroidism. "
12/01/1994 - "Oral bolus therapy and i.v. bolus therapy with alfacalcidol are equally effective in suppressing hyperparathyroidism. "
04/01/2008 - "This study was carried out to assess the efficacy of intravenous administration of alfacalcidol once weekly versus twice weekly in patients with severe hyperparathyroidism. "
06/01/2006 - "Feedback regulation of PTH with oral alfacalcidol therapy is efficient in the treatment of hyperparathyroidism. "
11/01/2004 - "Reversal of persistent hyperparathyroidism with the use of alfacalcidol may contribute to a decrease in skeletal morbidity."
05/01/1998 - "Only immature rats developed significant reduction of 1 alpha, 25 (OH)2 D3 and 25 OH D3, whereas only the adult rats developed significant hyperparathyroidism. "
10/01/1997 - "We conclude that oral 1 alpha (OH)D3 pulse therapy is effective for parathyroid activity suppression in patients with severe hyperparathyroidism. "
06/01/2012 - "Older people seemingly need higher 25(OH)D levels to offset age-associated hyperparathyroidism. "
11/01/2005 - "These findings suggest that the age-associated fall of serum 25(OH)D starts earlier in women than in men and that higher levels of 25(OH)D are required in older compared to younger persons to avoid the age-associated compensatory hyperparathyroidism."
11/01/2005 - "The aims of this research were to evaluate changes of 25(OH)D and PTH levels with age in a large population-based sample of men and women and to test the hypothesis that 25(OH)D serum concentrations needed to offset age-associated hyperparathyroidism are significantly higher in older than in younger persons. "
|10.||Octreotide (Sandostatin)FDA LinkGeneric
06/01/1997 - "Octreotide: effective treatment for hyperparathyroidism? "
08/01/1994 - "Octreotide may provide therapy for patients with hyperparathyroidism and for those who have undergone unsuccessful neck exploration or who are unfit for operation. "
11/27/1993 - "[Multiple type I endocrine neoplasms, effect of octreotide on hyperparathyroidism]."
05/01/1993 - "A patient with prolactinoma, resected insulinoma, hyperparathyroidism and ZES was not improved by a short course of octreotide (hypoglycemia); he died later of recurrent insulinoma. "
08/01/1994 - "This work examines the efficacy of the somatostatin analogue octreotide in the management of hyperparathyroidism. "
06/01/2014 - "Parathyroidectomy is the most cost-effective treatment for hyperparathyroidism. "
02/01/2007 - "Subtotal or total parathyroidectomy with reimplant represents the treatment of choice in refractory hyperparathyroidism with good results in most of the series reviewed."
01/01/2016 - "Editorial: Parathyroidectomy is safe and beneficial for patients with tertiary hyperparathyroidism, and should be the preferred therapy."
10/01/2006 - "Parathyroidectomy for hyperparathyroidism is associated with significant lasting improvement in subjective symptoms. "
12/01/2004 - "Near-total parathyroidectomy is beneficial for patients with secondary and tertiary hyperparathyroidism."
10/01/2011 - "This study suggests the need for testing of other interventions used for treatment of hyperparathyroidism which may help to offer better management of MBD after kidney transplantation."
01/01/1998 - "We concluded that spontaneous resolution of hyperparathyroidism after renal transplantation is uncommon. "
01/01/2015 - "The purpose of the study was to assess the results of operative treatment of patients with tertiary hyperparathyroidism (tHPT) after kidney transplantation. "
10/01/2013 - "In summary, this study demonstrates for the first time that persistent hyperparathyroidism is an independent risk factor for fractures after kidney transplantation."
10/01/2013 - "Only a few studies have reported the clinicopathological analysis of persistent hyperparathyroidism after kidney transplantation in long-term (>10 years) dialysis patients. "
|3.||Renal Dialysis (Hemodialysis)
01/01/2015 - "This study investigated the epidemiology of torus palatinus (TP) and torus mandibularis (TM) in hemodialysis patients and analyzed the influences of hyperparathyroidism on the formation of oral tori. "
05/01/2010 - "Articles concerning only type 1 and type 2 diabetes, hemodialysis, or hyperparathyroidism and studies in children were also excluded. "
01/01/2005 - "In conclusion, our study makes clear that hyperparathyroidism is a great threat to bone density in hemodialysis patients, mainly in the legs, the site mostly affected by fragility fractures in our patients. "
01/01/1996 - "A clinical correlative study of bone densitometric changes in hemodialysis patients with hyperparathyroidism."
12/01/1994 - "In this study, 16 hemodialysis patients with mild to moderate hyperparathyroidism were assigned, after a 4-wk run-in period, to receive a 6-wk course of either thrice-weekly i.v. or p.o. "
04/01/2002 - "Graft-dependent recurrent hyperparathyroidism occurred in one patient after 32 months and was cured by the selective removal of five enlarged autografts. "
07/01/2009 - "The purpose of the present study was to investigate the prevalence of hyperparathyroidism among a population of kidney graft recipients. "
04/01/2008 - "The objective of the present study was to assess the frequency and pathophysiological mechanisms responsible for the development of graft-dependent renal hyperparathyroidism (rHPT) after KTX. "
08/01/1995 - "The current studies clearly indicate that asymptomatic hyperparathyroidism is common even after 2 years post-renal transplant. "
12/01/2015 - "Posttransplant hyperparathyroidism increases the risk for all-cause mortality and graft loss, but not major cardiovascular events. "
|5.||Transplantation (Transplant Recipients)
05/01/1997 - "Therefore, our results provide no evidence for a spontaneous improvement of either persistent hyperparathyroidism or high bone turnover in normocalcemic long-term renal transplant recipients."
05/01/1997 - "No trend toward a spontaneous improvement of hyperparathyroidism and high bone turnover in normocalcemic long-term renal transplant recipients."
05/01/2008 - "Our study was aimed at identifying the predictors of hyperparathyroidism in renal transplant recipients. "
02/01/2015 - "Hyperparathyroidism is reported in 10% to 66% of renal transplant recipients (RTR). "
01/01/2014 - "PTH levels at 4 weeks post-transplantation might serve as a marker for the occurrence of hypercalcaemic hyperparathyroidism during follow-up."